Introduction {#s1}
============

Primary ovarian insufficiency (POI), also known as premature ovarian failure (POF) or premature menopause, is defined as cessation of menstruation before the expected age of menopause. This age is traditionally defined to be prior to 40 years and diagnosis is confirmed by elevated serum FSH levels (\>40IU/l). Although frequently stated that ∼1% of the population is affected with POI before the age of 40 years and 0.1% before age 30 years, the prevalence is actually less certain ([@DMV036C45]).

The disorder is clearly heterogeneous, with a wide spectrum of causes, namely cytogenetic, genetic, infectious or iatrogenic. Autoimmune and metabolic etiologies may or may not be genetic. Irrespective, etiology remains to be elucidated in most cases and until a decade ago few specific causes were known beyond X-chromosomal abnormalities, Fragile X mental retardation 1 (*FMR1*) premutation and FSH receptor (*FSHR*) in the Finnish population ([@DMV036C196]; [@DMV036C4]; [@DMV036C236]). Most cases of isolated POI still appear sporadically, but ∼10--15% has an affected first-degree relative, indicating significant genetic etiology ([@DMV036C218]). Pedigrees with multiple affected relatives are not rare (recessive and dominant). Presence of POI as one component of a pleiotropic genetic disorder is also well recognized. Yet identifying precise causative genes has been challenging. Here, we enumerate known genetic causes of POI, most elucidated within the last 5--10 years.

Confusion exists concerning nomenclature, namely the use of POF or POI. It is the view of the authors that POI can be taken to encompass occult, biochemical and overt stages, whereas POF is best considered as only the final stage of POI. The designation POI is thus best reserved as alluding to the entire gamut of disorders having diminished ovarian reserve---occult, subclinical, iatrogenic. Although many authors espouse POI in lieu of POF, the canonical genetic reference---Online Mendelian inheritance in man (OMIM)---has long used, and continues to use POF, to nominate causative genes. These designations now apply to POF1--POF9 ([Supplementary Table SI](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)), and the list growing.

Methods {#s2}
=======

A search for original articles published up to May 2015 was performed using PubMed and Google Scholar to identify studies on genetic variants associated with the human disease. The key word combinations include 'premature ovarian failure', 'primary ovarian insufficiency', 'early menopause', 'genetic', 'gene mutation', 'variant' and \'genome wide study'. For a study to be included in our review, it had to focus on chromosomal analysis, candidate gene screening, or a genome-wide study in different POI cohorts. In addition, studies on mitochondrial genes causing POI and multiple malformation syndromes characterized by POI were included. Reports on the role of candidate genes in animal models were not included. Where appropriate, reference lists of identified articles were also searched for further relevant papers. However, articles identified were restricted to English language full-text papers.

Results {#s3}
=======

Chromosomal abnormalities in POI {#s3a}
--------------------------------

Chromosomal abnormalities have long been recognized as a cause of POI, but percentages vary widely among reported series. This clearly reflects biases of ascertainment, for example reflecting whether a cohort was derived from a referral cytogenetic lab, a gynecologic practice, or a pediatric practice. Numerous different karyotypic anomalies have been found, ranging from numerical defects (monosomy X; X chromosomal mosaicism), X-deletions, X-autosome translocations, and X-isochromosomes and other rearrangements. Aggregate frequency of chromosomal abnormalities in reported studies is summarized in Table [I](#DMV036TB1){ref-type="table"}. Small sample sizes as well as selection biases and differing ages of ascertainment probably account for different prevalence in different populations. However, each of the five largest studies with respect to sample size reported frequencies between 10.0 and 12.9% ([@DMV036C242]; [@DMV036C118]; [@DMV036C12]; [@DMV036C99]; [@DMV036C101]); thus, a prevalence of 10--13% seems reasonable. Table IFrequency of chromosomal abnormalities (CA) in different population studies.ReferenceFrequency of CA (%)No. of CASample sizeClinical characteristicsPopulation[@DMV036C8]18.018100PA, SATunisian[@DMV036C101]10.0518179PA, SAIranian[@DMV036C99]12.164531PA, SAChinese (Jinan, Beijing, Shenzhen)[@DMV036C12]10.027269PA, SA, EMItalian[@DMV036C118]10.81081000PA, SATunisian[@DMV036C30]25.319^a^75SATurkish[@DMV036C95]12.919147SADutch[@DMV036C159]8.8890PA, SAFrench[@DMV036C242]12.513104POIChinese (Chongqing)[@DMV036C51]13.3430SAAmerican[@DMV036C48]2.5279PA, SA FSH\>20 IU/lEnglish[@DMV036C29]32.01547POIChilean[@DMV036C180]25.41663PA, SAAmerican[^1][^2][^3]

### Numerical defects {#s3a1}

The X chromosome has long been known to play an essential role in the maintenance of ovarian development and function. Females lacking an X chromosome as well as those showing an extra X chromosome are predisposed to developing POI.

### 45,X and 45,X/46,XX {#s3a2}

Turner syndrome, often but not universally associated with X monosomy, leads to ovarian dysgenesis and accelerated follicular atresia. X monosomy without mosaicism is more typically found in primary amenorrhea and cases were almost universally understood to present with this phenotype. However, many early series were recruited from pediatric clinics, not among adult women. In 1975, [@DMV036C196] reported that 3% (5/178) of 45,X patients actually menstruated. 45,X/46,XX and other forms of association also are associated with secondary amenorrhea (POI). Either haploinsufficiency of pivotal genes on the X chromosome or non-specific meiotic impairment could explain the accelerated atresia of 45,X oocytes. Variability would be expected given potential heterozygosity of alleles in genes subjected to X-inactivation.

### 47,XXX {#s3a3}

47,XXX women may experience oligomenorrhea, secondary amenorrhea, and early menopause, but relative risk has not been well studied. [@DMV036C83] reported the prevalence of 47,XXX in 52 women with POI to be 3.8%, whereas in our much larger Chinese series we observed 1.5% (8/531) ([@DMV036C99]). The presence of three X chromosomes plausibly leads to meiotic disturbance and, secondarily, ovarian failure. Additionally, overexpression of genes that escape X-inactivation could cause POI in 47,XXX. Mechanisms remain to be defined ([@DMV036C211]). A confounder is that an association exists between 47,XXX and autoimmune diseases ([@DMV036C90]; [@DMV036C83]).

### X-structural abnormalities and X-autosome translocations {#s3a4}

X chromosome deletions and X-autosome balanced translocations have long been observed in POI and were once the only approach available to localize causative genes. This strategy was illustrated in the 1970s by a region on the X chromosome appearing critical for the POI phenotype ([@DMV036C188]). A critical region was delineated that gave boundaries for breakpoints of X-autosome translocations associated with ovarian failure. This region extends from Xq13-Xq21 (POI2) to Xq23-q27 (POI1). It has been proposed by Rizzolio and colleagues that Xq13-Xq21 governs epigenetic regulations that down-regulate oocyte-expressed autosomal genes ([@DMV036C183], [@DMV036C184], [@DMV036C185]).

Irrespective of mechanisms involved in the critical region, almost all terminal deletions originating at Xq13 are associated with primary amenorrhea, lack of breast development and complete ovarian failure ([@DMV036C201]; [@DMV036C197]). By contrast, terminal deletions arising at Xq25 or Xq26 are characterized by the more common phenotype being not primary amenorrhea but premature ovarian failure. The gene designation POI1 is applied to this region. The more distal deletions arise at Xq27 or Xq28 and exert a less severe effect on stature and reproductive function than do proximal deletions ([@DMV036C196]; [@DMV036C201]). Gene(s) in this POI-causing region are considered distinct from Fragile X mental retardation 1 (*FMR1*), located at Xq27 and premutation of which is the most common single cause of POI.

Multiple genes on the X chromosome have been identified by X-autosomal translocations. These include Diaphanous-related formin 2 (*DIAPH2*, Xq22) ([@DMV036C15]), X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound (*XPNPEP2*, Xq25) ([@DMV036C162]), Dachshund family transcription factor 2 (*DACH2*, Xq21.3) ([@DMV036C163]), Premature ovarian failure, 1B (*POF1B*, Xq21.1) ([@DMV036C126]; [@DMV036C16]), Choroideremia (*CHM*, Xq21.1) ([@DMV036C126]; [@DMV036C132]), Progesterone receptor membrane component 1 (*PGRMC1*, Xq24) ([@DMV036C132]), Collagen, type IV, alpha 6 (*COL4A6*, Xq22.3) ([@DMV036C141]) and Nuclear RNA export factor 5 (*NXF5*, Xq22.1) ([@DMV036C13]). Some will individually be discussed below.

### Autosomal rearrangements {#s3a5}

Autosomal translocations---Robertsonian and reciprocal---have been observed in sporadic cases in Belgian, American, Japanese and Chinese women ([@DMV036C89]; [@DMV036C147]; [@DMV036C106]; [@DMV036C99]). Perturbations presumably confer haploinsufficiency or interrupt pivotal genes in these regions. Non-specific defective meiotic pairing or a position effect on contiguous genes is also a potential explanation ([@DMV036C197]; [@DMV036C152]). No autosomal region appears preferentially involved, long frustrating investigators seeking to use breakpoints to localize regions containing autosomal genes of relevance. Searches for autosomal regions disrupted in X-autosome translocations have similarly not proved fruitful in identifying autosomal roles in POI.

Single genes causing non-syndromic POI {#s3b}
--------------------------------------

Aside from regions of interest defined by chromosome deletions and translocations, the other traditional strategy to identify candidate genes in POI is to study genes whose product is known and plays a role in human folliculogenesis or shows an organ-specific effect based on murine knockout models (candidate genes). Many genes have been interrogated for these reasons. In this section we specifically review all genes for which data warrant strong consideration as a candidate gene for POI. Table [II](#DMV036TB2){ref-type="table"} and [Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1) contain available details of reported studies. Table IIVariants identified in candidate genes on the X chromosome for idiopathic and sporadic POI.GeneLocationCases (*N*)Controls (*N*)EthnicityMR^a^Sequence variationAmino acid changeFCMechanismReference*BMP15*Xp11.250214Caucasian North Africa Asia2 (4.0%)c.242A\>Gp.H81R[@DMV036C212]c.595G\>Ap.G199R100100Chinese1 (1.0%)c.985C\>Tp.R329C[@DMV036C230]300216Caucasian12 (4.0%)c.13A\>Cp.S5RYesSlightly affects transactivation of BRE-luc in COV434 granulosa cells[@DMV036C186]c.202C\>Tp.R68WMarkedly reduces mature protein production and affects transactivation of BRE-luc in COV434 granulosa cellsc.413G\>Ap.R138Hc.443T\>Cp.L148Pc.538G\>Ap.A180TNo effect on protein production or transactivation2093GermanyNone[@DMV036C122]9276ChineseNone[@DMV036C244]20354Caucasian African Asian3 (1.5%)c.443T\>Cp.L148P[@DMV036C115]c.538G\>Ap.A180Tc.468G\>ASensec.831T\>CSensec.852C\>TSense133197Indian14 (10.5%)c.181C\>Tp.R61W[@DMV036C62] and [@DMV036C92]c.182G\>Ap.R61Ec.226C\>Tp.R76CYesDecreased mature protein production, weaker Smad1/5/8 phosphorylation in COV434 cells and decreased granulosa cell proliferationc.227G\>Ap.R76Hc.538G\>Ap.A180Tc.538G\>T/c.539C\>Tp.A180F/S+Vc.588T\>Ap.N196Kc.617G\>Ap.R206HYesDecreased mature protein production, weaker Smad1/5/8 phosphorylation in COV434 cells and decreased granulosa cell proliferationc.631C\>Tp.E211Xc.661T\>Cp.W221Rc.727A\>Gp.L243Gc.381A\>GSensec.\*40dupG3′UTR166181Caucasian7 (4.2%)c.202C\>Tp.R68W[@DMV036C56], [@DMV036C57]c.538G\>Ap.A180Tc.704A\>Gp.Y235CYesDiminished GC proliferation with a dominant negative effect3851New ZealandNone[@DMV036C31]153JapaneseNone[@DMV036C209]*AR*Xq12133200Indian2 (1.5%)c.1948A\>Gp.T650A[@DMV036C149]c.1972C\>Ap.O658Kc.1885+9C\>AIntron*FOXO4*Xq13.1116143TunisianNone[@DMV036C73]*POF1B*Xq21.2223900Italian2 (0.9%)c.G1477Ap.C444Y[@DMV036C16]*DACH2*Xq21.32571110Italian2 (0.8%)c.G274Tp.R37L[@DMV036C16]c.T1111Cp.F316S*PGRMC1*Xq22-q2467153Swedish Italian1 (1.5%)c.494A\>Gp.H165RYesAttenuates ability to transduce progesterone\'s anti-apoptotic action in granulosa cells and abolishes binding capacity to CYP7A1[@DMV036C132]196200Chinese1 (0.51%)c.556C\>Tp.P186S[@DMV036C234][^4][^5]

Variants occurring in evolutionary conserved regions are more likely to carry functional significance. These include missense, nonsense, insertion or deletion variants and were considered as plausible causative variants with clinical significance. Thus, perturbations should yield a severe functional defect. A nonsense mutation that results in truncated protein should lead to haploinsufficiency; a splicing site mutation or insertion/deletion should result in a frameshift that leads to a different protein product; a missense mutation may change the amino acid and cause a dominant negative effect.

Those regions or genes found only by genome-wide studies, including genome-wide association study, cytogenomic study, whole-exome sequencing, and next generation sequencing (NGS), are cited separately.

### Genes on the X chromosome {#s3b1}

#### Bone morphogenetic protein 15 (BMP15) (Xp11.2) {#s3b1a}

*BMP15* is located on chromosome Xp11.2. The possible involvement of *BMP15* in POI pathogenesis was initially supported by evidence from animal models. Inverdale and Hanna sheep with a naturally occurring *Bmp15* mutation had increased ovulation rate and twin and triplet births in heterozygotes, but ovarian failure results from impaired follicular development beyond the primary stage in homozygotes ([@DMV036C79]). *Bmp15* knockout female mice also were subfertile, showing decreased ovulation rates, reduced litter size and decreased number of litters per lifetime ([@DMV036C240]).

In humans *BMP15* was first implicated in POI by [@DMV036C56], who reported a heterozygous p.Y235C missense mutation in each of two sisters having ovarian failure. The authors presented *in vitro* evidence for a dominant negative mechanism. Other variants have been identified in Caucasian, Indian and Chinese women with POI, albeit with quite different frequencies (1.5--15%) ([@DMV036C57]; [@DMV036C62]; [@DMV036C115]; [@DMV036C122]; [@DMV036C117], [@DMV036C119]; [@DMV036C186]; [@DMV036C230]). Merely showing different frequencies between a given single nucleotide polymorphism (SNP) in POI and control is a less robust method than finding a unique perturbation with functional validation in a case ([@DMV036C244]; [@DMV036C122]). However, some variants found in higher frequency indeed show marked reduction of mature protein production ([@DMV036C186]).

Of relevance is that *BMP15* is a member of the transforming growth factor (TGF) family, with dimerization occurring with other TGF proteins such as *GDF9*, to be discussed below. Most reported *BMP15* variants are, in fact, in the region corresponding to the propeptide of the protein, which is essential for dimerization and subsequent post-translational processing into biologically active proteins.

#### Progesterone receptor membrane component 1 (PGRMC1) (Xq22-q24) {#s3b1b}

*PGRMC1* was first described in 1998 as a putative progesterone-binding membrane receptor ([@DMV036C127]). This protein is expressed in various tissues, e.g. liver, kidney, adrenal glands, uterus and leukocytes and involves progesterone signaling in the reproductive system ([@DMV036C28]; [@DMV036C127]; [@DMV036C132]). PGRMC1 mediates progesterone\'s anti-apoptotic effects on granulosa cells ([@DMV036C67]; [@DMV036C151]; [@DMV036C127]; [@DMV036C132]).

[@DMV036C132] identified a mother and daughter with POI, both of whom carried an X;autosome translocation \[t(X;11)(q24;q13)\]. Systematic mapping of the Xq breakpoint and performing RNA expression studies revealed reduced expression of *PGRMC1*. Mutation screening of 67 females with idiopathic POI identified a third patient having a missense mutation (p.H165R), located in the cytochrome b5 domain. The p.H165R mutation abolishes binding of cytochrome P450 7A1 (CYP7A1) to PGRMC1 and attenuates PGRMC1\'s ability to mediate the anti-apoptotic action of progesterone in ovarian cells. These findings suggest that mutant or reduced levels of PGRMC1 may cause POI through impaired activation of the microsomal cytochrome P450 and increased apoptosis of ovarian cells. A recent study in Chinese patients with POI identified a novel missense mutation (C.556C\>T, p. P186S), but there was no functional study to confirm a deleterious effect ([@DMV036C234]).

#### Androgen receptor (AR) (Xq12) {#s3b1c}

The *AR* gene encodes the androgen receptor and is involved in sex differentiation and reproduction. Its perturbation in 46,XY individuals results in the well-known sex reversed phenotype of androgen insensitivity, testosterone produced by testis exerting no effect on androgen-dependent differentiation. In the ovary, AR is expressed in developing follicles, mainly granulosa cells. Deficiency of *Ar* in female mice results in a POI-like phenotype and dysregulation of a number of major genes critical for folliculogenesis, indicating that normal folliculogenesis requires AR-mediated androgen action ([@DMV036C194]). An association between CAG repeat length in exon 1 of the *AR* gene and POI has been proposed but remains controversial ([@DMV036C25]; [@DMV036C36]; [@DMV036C206]; [@DMV036C149]). An example is a repeat of two missense mutations (p.T650A and p.O658K) in Indian women with POI ([@DMV036C149]).

#### Forkhead box O4 (FOXO4) (Xq13.1) {#s3b1d}

The *FOXO4* gene encodes a member of the O class of winged helix/forkhead transcription factor family (FOXO). FOXO4 is expressed in granulosa cells in mice and human, and is involved in the PI3K (phosphoinositide 3-kinase)/Akt (v-akt murine thymoma viral oncogene homolog 1)/Cdkn1b (cyclin-dependent kinase inhibitor 1B) molecular pathway, which suggests a functional role in ovarian physiology ([@DMV036C158]). Mutation screening in 116 Tunisian patients identified only one intronic variant; IVS2 + 41T\>G; therefore, *FOXO4* might not be a common cause of POI in the Tunisian population ([@DMV036C73]).

#### Premature ovarian failure, 1B (POF1B) (Xq21.2) {#s3b1e}

Alluded to previously, this 'gene' is actually a region, but codified by OMIM. Its significance is its location within the critical POI1 region. It was found to be interrupted by a breakpoint in an X-autosome translocation in a patient with secondary amenorrhea (POI). Subsequent mutation analysis in an Italian POI cohort (*N* = 223) only revealed 30 SNPs ([@DMV036C16]). In a Lebanese family having ﬁve sisters with POI, [@DMV036C114] established linkage to Xq21 using whole-genome SNP typing and homozygosity-by-descent mapping. Sequencing identiﬁed a homozygous p.R329Q mutation, which impaired the capacity to bind nonmuscle actin ﬁlaments, and might lead to exaggerated germ-cell apoptosis and POI.

#### Dachshund family transcription factor 2 (DACH2) (Xq21.3) {#s3b1f}

*DACH2*, also named dachshund family transcription factor 2, is located on Xq21.3. It was first identified by fine mapping of the disrupted region in an X;autosome translocation in POI patients ([@DMV036C163]). Subsequent mutation screening revealed two novel missense mutations---p.R37L and p.F316S---in an Italian cohort of POI patients ([@DMV036C16]). However, no subsequent evidence of involvement of *DACH2* in mammalian gonads or additional mutations in other ethnic population has been reported.

#### Fragile X mental retardation 1 (FMR1) (Xq27.3) {#s3b1g}

One of the commonest causes of POI is a premutation of *FMR1*, which when fully perturbed (\>200 CGG repeats) causes fragile X syndrome but paradoxically not POI. A prototype of pleiotropic single gene disorders in which POI is one component, *FMR1* is discussed in the 'Pleiotropic Single Gene Disorders Having POI' section, along with other pleiotropic genes.

### Genes on autosomes {#s3b2}

In this section we will review autosomal genes for which data appear to warrant strong consideration as a candidate gene for POI. [Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1) contains available details on studies generating this conclusion.

#### Growth differentiation factor 9 (GDF9) (5q31.1) {#s3b2a}

Expressed in oocytes, *GDF9* is an attractive candidate gene for POI because it is, like *BMP15*, a member of the TGF gene family. Increased frequencies of certain novel variants have been detected in European, Caucasian and Asian patients ([@DMV036C59]; [@DMV036C115]; [@DMV036C111]; [@DMV036C246]), but not in Japanese and New Zealand populations ([@DMV036C209]; [@DMV036C31]). All variants were heterozygous. Recently, high-resolution array comparative genomic hybridization (CGH) (2.2 kb resolution) was applied in 26 POI Swedish cases, finding one partial *GDF9* gene duplication (475 bp) ([@DMV036C142]). Unfortunately, parents were not available to exclude a heritable copy number variant (CNV) less likely to carry significance. This pitfall is discussed further in 'Genome-Wide Studies in POI' section.

Heterozygous changes could result in a dominant negative effect, quite plausible given dimerization with fellow members of the TGF gene family (e.g. BMP15). The proportion of POI due to *GDF9* perturbations is, however, unclear. If a hydrophobic amino acid replacing a hydrophilic amino acid were causative, *GDF9* perturbations could account for a substantial number (1--4%) of POI cases.

#### Folliculogenesis specific bHLH transcription factor (FIGLA) (2p13.3) {#s3b2b}

*FIGLA*, also named factor in the germline, alpha, is a germ-cell specific, basic helix-loop-helix (bHLH) transcription factor, that plays a crucial role in the formation of the primordial follicle and coordinates expression of zona pellucida genes. [@DMV036C247] screened 100 Chinese women with POI and identified three variants in four women: missense mutation p.A4E in two women; deletion p.G6fsX66 in one woman, resulting in a frameshift that leads to haploinsufficiency; and deletion p.140delN in a fourth woman. Functional analyses by the yeast two-hybrid assay demonstrated that the p.140delN mutation disrupted FIGLA binding to the TCF3 helix-loop-helix (HLH) domain. These findings show that a subset of Chinese women with sporadic POI harbor mutations in *FIGLA*. Recently, another novel intronic variant was found in 219 Indian POI cases ([@DMV036C215]). Further functional validation is warranted.

#### Newborn ovary homeobox gene (NOBOX) (7q35) {#s3b2c}

*NOBOX* is an oocyte-specific homeobox gene that plays a critical role in early folliculogenesis. The causative role was discovered by [@DMV036C179]. In mice *Nobox* deficiency disrupted early folliculogenesis and oocyte-specific gene expression. Lack of *Nobox* accelerated post-natal oocyte loss and abolished the transition from primordial to growing follicles in mice. In female mice lacking *Nobox,* follicles are replaced by fibrous tissue in a manner similar to non-syndromic ovarian failure in women. Genes preferentially expressed in oocytes, including *Pou5f1* (POU class 5 homeobox 1) and *Gdf9*, are also down-regulated in *Nobox^−/−^* mice. [@DMV036C121] showed that POI in *Nobox* deficient mice results from faulty signaling between somatic and germ line components during embryonic development. In addition, the extremely unusual presence of abnormal adherens junctions between unseparated oocytes within syncytial follicles indicates that faulty communication between somatic and germ cells is involved in, or leads to, abnormalities in the cell adhesion program. [@DMV036C167] were the first to demonstrate that a perturbation (p.R355H) in *NOBOX* was responsible for human POI. The mutation disrupted NOBOX homeodomain binding to NOBOX DNA-binding element (NBE) and had a dominant negative effect. Our functional studies demonstrated that haploinsufficiency was involved in the genetic mechanism in humans for POI. Mutations in the homeobox domain of *NOBOX* proved not to be a common explanation for POI in Chinese women (0/200) ([@DMV036C170]) but [@DMV036C23], [@DMV036C24]) subsequently reported that novel *NOBOX* loss-of-function mutations accounted for 6.2 and 5.6%, respectively, of cases in two large 'primary ovarian insufficiency' cohorts of Caucasian and African ancestry.

#### Nuclear receptor subfamily 5, group A, member 1 (NR5A1); Steroidogenic factor-1(SF-1) (9q33) {#s3b2d}

*NR5A1* encodes an orphan nuclear receptor that regulates transcription of an array of genes involved in reproduction, steroidogenesis and male sexual differentiation. These include anti-Mullerian hormone (*AMH*), Nuclear receptor subfamily 0, group B, member 1 (*DAX1*), Cytochrome P450, family 11, subfamily A, polypeptide 1 (*CYP11A*), steroidogenic acute regulatory protein (*StAR*), as well as genes encoding steroid hydroxylases, gonadotrophins, and aromatase. Inactivation of *Nr5a1* specifically in mouse granulosa cells causes infertility associated with hypoplastic ovaries.

[@DMV036C153] identified *NR5A1* mutations as a frequent cause of 'primary amenorrhea' in 46,XY phenotypic female adolescents with a low testosterone concentration. [@DMV036C128] sequenced *NR5A1* in four families (each having at least one family member with a 46,XY disorder of sex development and another with 46,XX POI) and 25 subjects with sporadic POI, and they identified 19 different mutations in the *NR5A1* gene. Functional studies indicated that these mutations substantially impaired the transactivational activity of *NR5A1*. Subsequently additional mutations were identified in different ethnicities with low frequencies ([Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)). [@DMV036C96] sequenced the coding regions of *NR5A1* in a large, well-phenotyped cohort of 356 Dutch women with POI, finding 9 different mutations in 10 patients. Functional prediction showed low to intermediate pathogenicity for all non-conserved mutations. However, the novel p.Y5D mutation, detected in a non-domain region, was presumed to result in haploinsufficiency in Chinese patients with POI ([@DMV036C100]).

#### FSH receptor (FSHR) (2p21-p16) {#s3b2e}

FSH/FSHR signaling plays a key role in normal gonadal function by regulating follicular growth, estrogen production and oocyte maturation. Mutation in *FSHR* was the first autosomal molecular explanation for POI, elucidated prior to the contemporary era. [@DMV036C3] and [@DMV036C4], [@DMV036C5] ascertained 75 primary or secondary amenorrhea cases, and found homozygous mutations (c.566C\>T, p.A189V), in the extracellular portion of this G-protein receptor, in women of six Finnish families with hypergonadotrophic ovarian dysgenesis. This mutation resulted in a dramatic reduction of binding capacity and signal transduction, but with apparently normal ligand-binding affinity ([@DMV036C4]). The frequency of the c.566C\>T mutation is 0.96% in a Finnish population ([@DMV036C98]). However, subsequent screening in cohorts of different ethnicities seldom found mutations ([@DMV036C47]; [@DMV036C98]; [@DMV036C44]; [@DMV036C208]; [@DMV036C213]; [@DMV036C207]; [@DMV036C37]; [@DMV036C122]; [@DMV036C220]; [@DMV036C160]; [@DMV036C237]). Therefore, *FSHR* mutations are not uncommon in XX gonadal dysgenesis in Finland, but apparently rare elsewhere ([Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)).

#### TGF, beta receptor III (TGFBR3) (1p33-p32) {#s3b2f}

Human *TGFBR3* is located at 1p33-p32 and encodes the TGF-beta type III receptor. The encoded receptor is a membrane proteoglycan that often functions as a co-receptor with other TGF-beta receptor superfamily members. Two missense variants, p.E459G and p.P825L, were identified in Chinese women with idiopathic POI, both predicted to have functional and structural impacts on the TGFBR3 protein ([@DMV036C171]). Another missense mutation---p.P775S---was found in an Indian POI case ([@DMV036C61]).

#### G protein-coupled receptor 3 (GPR3) (1p36.1-p35) {#s3b2g}

The *GPR3* gene, located in 1p36.1-p35 and having 2 exons, is a member of the G protein-coupled receptor family. Predominantly expressed in oocytes, *GPR3* maintains meiotic arrest in antral follicles until the LH surge through pathways involved in cAMP and cGMP regulation. In *Gpr3^−/−^* mice, the majority of oocytes in antral follicles had unscheduled premature resumption of meiosis ([@DMV036C138]). A synonymous variant (c.135G\>A, p.V45V) was found in one Chinese patient ([@DMV036C252]), and another study also failed to find any potential disease-associated changes in 82 North American Caucasian women with POI ([@DMV036C112]).

#### Wingless-type MMTV integration site family, member 4 (WNT4) (1p36.23-p35.1) {#s3b2h}

*WNT4* encodes a secreted extracellular signaling protein that is expressed in human ovaries early in fetal development ([@DMV036C94]), and plays a critical role in female sex determination and differentiation. In the ovaries of *Wnt4* mutant mice, the rate of apoptosis was similar to that of wild type mice at birth; however, apoptotic cells progressively increased during follicular development ([@DMV036C94]). By sequencing the coding region of *WNT4* in 55 Tunisian women with POI, a synonymous variant in exon 2 (c.99G\>A, p.S33S) was identified ([@DMV036C120]). Mutational analysis was also performed in 145 Chinese women with POI with no causative variants found ([@DMV036C39]).

#### Inhibins: inhibin, alpha (INHA) (2q35); inhibin, beta A (INHBA) (7p15-p13); inhibin, beta B (INHBB) (2cen-q13) {#s3b2i}

Inhibin is a dimeric glycoprotein hormone. Belonging, like BMP-15 and GDF9, to the superfamily of TGF-β, inhibin is a negative regulator of FSH. Inhibin encompasses inhibin, alpha (*INHA*) (2q35), inhibin, beta A (*INHBA*) (7p15-p13), and inhibin, beta B (*INHBB*) (2cen-q13).

The missense mutation c.769G\>A (p.A257T) in the *INHA* gene was more frequently found in patients with POI in New Zealand (7%) ([@DMV036C191]), India (11.2%) ([@DMV036C58]) and Italy (4.5%) ([@DMV036C133]). Increased susceptibility to POI was associated with impaired inhibin B bioactivity ([@DMV036C32]). The additional novel missense mutations c.275G\>A (p.S92N), c.525C\>G (p.H175Q) and c.545C\>A (p.A182D) were exclusively identified in Indian POI patients (1.25% for each mutation) ([@DMV036C60]). It is unclear whether polymorphisms in the *INHA* promoter result in reduced inhibin expression, but the promoter variant c.-16C\>T was signiﬁcantly under-represented in patients with POI in New Zealand ([@DMV036C88]). The *INHBA* and *INHBB* gene encode inhibin βA and inhibin βB subunits. Causative mutations were not found in the two genes, however, except possibly for one synonymous mutation c.1032C\>T in the *INHBA* gene ([@DMV036C191]; [@DMV036C34]).

#### POU class 5 homeobox 1 (POU5F1) (6p21.31) {#s3b2j}

The *POU5F1* transcription factor gene, located on 6p21.31, is significantly down-regulated in *Nobox* knockout mice. Thus, *POU5F1* becomes a potential candidate gene for POI, a downstream target of *NOBOX*. [@DMV036C231] sequenced 175 Chinese POI cases and found one non-synonymous variant (p.P13T), a heterozygous hydrophobic to hydrophilic substitution.

#### MutS homolog 4 (MSH4) (1p31) and *MSH5* (6p21.3) {#s3b2k}

*MSH4* and *MSH5* belong to the DNA mismatch repair gene family, playing pivotal roles in meiotic recombination. Mammalian MSH4 and MSH5 proteins form a heterodimeric complex and exert essential functions for normal chromosome synapsis during zygotene. Disruption of *Msh4* or *Msh5* in female mice resulted in sterility, degenerated ovaries and progressive loss of oocytes due to meiotic failure ([@DMV036C53]; [@DMV036C109]). In a case--control study in a Caucasian population, in which both genes were sequenced, a heterozygous mutation p.P29S in *MSH5* was found in 2 of 41 cases. The mutation was located in the Hmsh4-binding domain of *MSH5* which could disrupt the integrity of the protein interaction between MSH5 and MSH4 ([@DMV036C131]).

#### Forkhead box O3 (FOXO3) (6q21) {#s3b2l}

Forkhead transcription factor *FOXO3*, located at 6q21, encodes a master regulator and potent suppressor of primordial follicle activation. Loss of *Foxo3* function in mice leads to POI due to global follicle activation ([@DMV036C124]). The frequency of variants in POI patients differs in different ethnic groups ([Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)), but in several populations the frequencies of *FOXO3* variants are not insignificant (6% in French and 13.3% in Chinese). However, the pathological role of these variants needs to be determined by functional studies.

#### Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 (CITED2) (6q23.3) {#s3b2m}

*CITED2* is essential for early embryonic development. This is evidenced by delayed differentiation of gonads in *Cited2^−/−^* mice ([@DMV036C43]). Fonseca and colleagues reported a novel missense mutation p.P202T in one of 116 Tunisian POI cases ([@DMV036C74]). Further studies in other populations are warranted.

#### Spermatogenesis and oogenesis specific basic helix-loop-helix transcription factor 1 (SOHLH1) (9q34.3) and SOHLH2 (13q13.3) {#s3b2n}

As germ cell specific master-master transcription factors, SOHLH1 and SOHLH2 orchestrate different oocyte-specific genes essential for early folliculogenesis. *Sohlh1/2*-deficient mice exhibit atrophied ovaries devoid of follicles due to defective primordial-to-primary follicle transition ([@DMV036C150]; [@DMV036C42]). Novel distinct heterozygous variants were identified in both *SOHLH1* and *SOHLH2* in large cohorts of women with POI of Han Chinese and Serbian origin ([@DMV036C175]; [@DMV036C250]). Plausible pathogenesis might involve disturbing the expression, transactivation or homo-/hetero-dimerization of SOHLH1 or SOHLH2 proteins. No subsequent reports exist, to our knowledge.

#### Phosphatase and tensin homolog (PTEN) (10q23.3) {#s3b2o}

Localized on chromosome 10q23.3, *PTEN* plays a causative role in early activation of primordial follicles by negatively regulating the PI3K pathway ([@DMV036C181]). Primordial follicles become depleted in *Pten* null mice in early adulthood, mimicking the phenotype of POI in humans. However, no causative mutation was detected in coding regions of *PTEN* gene in Japanese and Chinese women with POI ([@DMV036C195]; [@DMV036C248]).

#### Nanos homolog 1, 2, 3 (Drosophila) (NANOS1, 10q26.11; NANOS2, 19q13.32; NANOS3, 19p13.13) {#s3b2p}

The *NANOS* gene family is known to be required for primordial germ cell (PGC) development and maintenance. Three homologs (*NANOS1*, *NANOS2* and *NANOS3*) exist. Disruption of *Nanos1* in mice did not affect germ cell development, but knockout of *Nanos2* or *Nanos3* resulted in infertility with decreased gonad size due to loss of PGC. *Nanos2* deficiency only resulted in spermatogonia loss whereas *Nanos3* impaired PGC maintenance in both males and females ([@DMV036C216]).

Mutations in *NANOS3* were investigated in 80 Chinese and 88 Caucasian women with POI ([@DMV036C168]). No causative mutations were found in coding exons. However, one potentially relevant heterozygous mutation (c.457C\>T; p.R153W) was identified in another study involving 100 Chinese POI patients ([@DMV036C239]). Functional studies showed decreased stability of NANOS3, potentially resulting in a hypomorph. And a homozygous mutation (c.358G\>A, p.E120K) was found in two sisters with primary amenorrhea from 85 Brazilian women with POI. *In vitro* and in silico functional studies revealed that this mutation impaired the ability of NANOS3 to prevent apoptosis, suggesting a mechanism for POI involving increased PGC apoptosis during embryonic cell migration ([@DMV036C187]). Taken together, these results suggest a role for *NANOS3* mutation in some cases of POI.

#### Cyclin-dependent kinase inhibitor 1B (CDKN1B) (12p13.1-p12) {#s3b2q}

*CDKN1B*, also known as *P27* and *KIP1*, encodes a cyclin-dependent kinase inhibitor that regulates proliferation and differentiation in many tissues. It suppresses ovarian follicle endowment and activation, and promotes follicle atresia. Premature follicle depletion occurred due to accelerated activation in *Cdkn1b* knockout mice ([@DMV036C178]). Sequence analysis of *CDKN1B* found one novel heterozygous mutation c.356T\>C (p.I119T) in one of 87 Tunisia POI patients ([@DMV036C144]). However, no variants were identified in Chinese cohorts ([@DMV036C229]; [@DMV036C249]), suggesting that mutations in *CDKN1B* are not common in POI, at least in this population.

#### Anti-Mullerian hormone receptor, type II (AMHR2) (12q13) {#s3b2r}

*AMHR2* encodes a receptor in the AMH pathway which plays a crucial role in the development and maintenance of reproductive organs in mammals. Polymorphism c.-482 A\>G (rs2002555) in *AMHR2* was revealed to be associated with age at menopause in interaction with parity in Dutch women, but no association was found with POI in Korean and Chinese women ([@DMV036C241]; [@DMV036C176]). Negative results in *AMHR2* were also reported in 16 Japanese women with POI ([@DMV036C226]). However, [@DMV036C176] identified two novel missense mutations (p.I209N and p.L354F) in a cohort of Chinese POI women.

#### KIT ligand (KITLG) (12q22) {#s3b2s}

The human *KITLG* gene, located at 12q22, encodes the ligand of a tyrosine-kinase receptor. KIT/KITLG plays a critical role during oogenesis and folliculogenesis. Mice with a deficiency in *Kitlg* manifested impaired PGCs ([@DMV036C135]). However, no perturbations were reported in the coding region of *KITLG* from 40 Caucasian POI patients ([@DMV036C91]).

#### Forkhead box O1 (FOXO1) (13q14.1) {#s3b2t}

*FOXO1*, another member of the forkhead family of transcription factors, is important in granulosa cell function and follicle maturation. [@DMV036C235] identified one 5′UTR mutation (c.-30C\>T) and one missense mutation (p.P84L) in 60 New Zealand and Slovenia POI patients.

#### Spalt-like transcription factor 4 (SALL4) (20q13.2) {#s3b2u}

SALL4, a zinc ﬁnger transcription factor, is expressed in murine oocytes. SALL4 binds to POU5F1 and could regulate its expression. Both *Sall4* and *Pou5f1* are drastically down-regulated in *Nobox^−/−^* newborn ovaries ([@DMV036C243]; [@DMV036C41]). [@DMV036C227] screened the coding regions of *SALL4* in 100 Han Chinese females with non-syndromic POI and identified two heterozygous missense mutations (p.V181M and p.T817A) in the conserved region. These may or may not be POI-associated gene variants. Further studies are needed to determine the functional effect of these variants.

#### Meiotic protein covalently bound to DSB (SPO11) (20q13.31) {#s3b2v}

*SPO11* is involved in meiosis, forming the double-strand breaks (DSBs) that initiate meiotic recombination. *Spo11^−/−^* mice are infertile with premature depletion of oocyte because of defective meiosis. However, no novel variants were found in 41 women with non-syndromic POI ([@DMV036C131]). It is not clear whether an association between *SPO11* mutation and sporadic POI exists in human.

#### DNA meiotic recombinase 1 (DMC1) (22q13.1) {#s3b2w}

Genes perturbing meiosis are logical candidates for non-syndromic POI. *DMC1* encodes a member of the superfamily of recombinases, which are important for repairing double- strand DNA breaks during mitosis and meiosis. Among 41 French women with POI, [@DMV036C131] found one POI case with homozygous mutation p.M200V. However, a subsequent screening revealed no mutation but two known SNPs in 192 Chinese women with POI ([@DMV036C232]).

Pleiotropic single gene disorders in POI {#s3c}
----------------------------------------

Distinct from non-syndromic POI, pleiotropic Mendelian disorders may manifest POI as part of their phenotypic spectrum. Indeed, the most common single genetic explanation for POI is represented by such a disorder---premutation for fragile X syndrome (Table [III](#DMV036TB3){ref-type="table"}). Table IIICandidate genes responsible for Mendelian disorders that manifest POI.GeneLocationMendelian syndromeSomatic featuresReference*FMR1*Xq27.3Fragile X syndromeAttention deficits, hyperactivity, social deficits, anxiety disorder, deficits in cognitive flexibility.[@DMV036C182] and [@DMV036C203]*FOXL2*3q23Blepharophimosis-ptosis-epicanthus BPE type I syndrome, BPES IBPES type I is a complex eyelid malformation associated with POI. The major features of the eyelid malformation involve (i) narrowed horizontal aperture of the eyelids (blepharophimosis), (ii) drooping of the upper eyelid (ptosis), (iii) the presence of a fold of skin arising from the lower eyelid that runs inward and upward (epicanthus inversus), and (iv) lateral displacement of the inner canthi (telecanthus).[@DMV036C253] and [@DMV036C146]*GALT*9p13GalactosemiaCataracts, speech defects, poor growth, poor intellectual function, neurologic deficits (predominantly extrapyramidal findings with ataxia).[@DMV036C189]*AIRE*21q22.3Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome, APECEDCandidiasis, Addison\'s disease, hypoparathyroidism, type 1 diabetes, alopecia, vitiligo, ectodermal dystrophy, celiac disease and other intestinal dysfunctions, chronic atrophic gastritis, chronic active hepatitis, autoimmune thyroid disorders, pernicious anemia.[@DMV036C70]*EIF2B*EIF2B2 -14q24.3; EIF2B4-\
2p23.3; EIF2B5-\
3q27.1Central nervous system leukodystrophy and ovarian failure, ovarioleukodystrophyNeurological disorder characterized by involvement of the white matter of the central nervous system. When Leukodystrophies associated with premature ovarian failure referred to as ovarioleukodystrophy.[@DMV036C134]*POLG*15q25Progressive external ophthalmoplegia, PEOManifestations range from involvement limited to the eyelids and extraocular muscles.[@DMV036C84]*NOG*17q22Proximal symphalangism, SYM1Ankylosis of the proximalinterphalangeal joints.[@DMV036C110]*PMM2*16p13PMM2-CDG CDG-1 (a previously known as congenital disorder of glycosylation type 1a)Cerebellar dysfunction (ataxia, dysarthria, dysmetria), non-progressive cognitive impairment, stroke-like episodes, peripheral neuropathy with or without muscle wasting, absent puberty in females, small testes in males, retinitis pigmentosa, progressive scoliosis with truncal shortening, joint contractures, and premature aging[@DMV036C202]*HSD17B4*\
*HARS2*\
*CLPP*\
*LARS2*\
*C10orf2*5q21\
5q31.3\
19p13.3\
3p21.3\
10q24Perrault syndrome, PSSensorineural deafness in both males and females, and neurological manifestations in some patients.[@DMV036C97], [@DMV036C139], [@DMV036C156], [@DMV036C157] and [@DMV036C155]*BLM*15q26.1Bloom syndromeChromosomal breakage leading to early onset of aging, short stature and elevated rates of most cancers.[@DMV036C65]*ATM*11q22-q23Ataxia telangiectasia, A-TProgressive cerebellar degeneration, telangiectasias, immunodeficiency, recurrent infections, insulin-resistant diabetes, premature aging, radiosensitivity, and high risk for epithelial cancers in surviving adults.[@DMV036C80] and [@DMV036C205]*WRN*8p12Werner syndromePremature aging of the skin, vasculature, and bone and elevated rates of certain cancers, particularly sarcomas.[@DMV036C68]*RECQL4*8q24.3Rothmund--Thomson syndrome, RTSCutaneous rash, sparse hair, small stature, skeletal and dental abnormalities, cataracts, premature aging, and an increased risk for cancer, especially malignancies originating from bone and skin tissue.[@DMV036C225][^6]

### Fragile X syndrome: familial mental retardation 1 (FMR1) (Xq27.3) {#s3c1}

Perturbations of *FMR1* are responsible for fragile X syndrome. Clinical features include mental retardation, characteristic facial features with large ears and prominent jaw, connective tissue findings (joint laxity), large testes after puberty, and behavioral abnormalities. Fragile X syndrome occurs in males when CGG repeats number above 200. In females ∼70% of women with \>200 CGG repeats show intellectual disability ([@DMV036C52]). The incidence of fragile X syndrome in males is approximately 1 in 4000, and in females 1 in 8000 ([@DMV036C2])

The normal number of CGG repeats in *FMR1* is 32. Thereafter, there is a stage (premutation) in which 54--200 CGG repeats exist. Pathogenic effects including mental retardation and ataxia may exist, as well as POI. About 15--20% of women with a FMR1 premutation develop POI ([@DMV036C236]). Conversely, 5% of sporadic cases and 10--15% of familial cases in the Caucasian population are explained by *FMR1* premutations. For reasons that are not clear, the number of CGG repeats significantly correlates with risk of POI only within selected ranges. There is only a slightly increased risk of expansion associated with 40--79 repeats; but higher risk with 80--99 repeats, yet no further increased risk occurs after \>100 repeats, and as noted POI is not observed with the full mutation (\>200 CGG) ([@DMV036C7]). One possible explanation is that certain genes are suppressed in the 54--100 premutation range and link to POI, whereas other genes become suppressed only with higher numbers of CGG repeats. Perhaps, then, phenotypes in the two groups differ because some ovarian genes are inhibitory and others are the converse. Thus, ovarian function may be initially suppressed but later return to normal function.

Given the comparatively higher frequency of premutation of *FMR1* in POI than the general population ([Supplemental Table SIII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)), *FMR1* testing has become part of the work-up for women with POI. It is formally recommended in Europe ([@DMV036C76]; [@DMV036C69]). In other populations the prevalence is lower. [@DMV036C86] reported that only 2 premutation carriers were found in 379 sporadic Chinese POI cases (0.49%); none were found in 402 controls. The frequency in Chinese women is thus considerably lower than in Caucasian women (3.3--6.7%). Frequencies are 1.56% in Japanese ([@DMV036C93]) and 4.8% in Slovenian women ([@DMV036C81]).

### Blepharophimosis-ptosis-epicanthus syndrome (BPES): forkhead box L2 (FOXL2) (3q23) {#s3c2}

Blepharophimosis-ptosis-epicanthus syndrome (BPES) is a pleiotropic autosomal dominant syndrome in which *FOXL2* is perturbed and premature ovarian failure occurs ([@DMV036C46]). That *FOXL2* plays a key if not the pivotal role in ovarian development initially came from study of BPES kindreds. More than one hundred unique *FOXL2* mutations have now been described in BPES in different populations ([@DMV036C14]). By contrast, constitutional mutations are uncommon but reported in non-syndromic POI. Perhaps 2--3% of isolated POI cases have a *FOXL2* mutation ([@DMV036C50]; [@DMV036C87]) ([Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)).

### Galactosemia: galactose 1-phosphate uridyl transferase (GALT) (9p13) {#s3c3}

Galactosemia is caused by deficiency of galactose 1-phosphate uridyl transferase (*GALT*). Ovarian failure is a common long-term complication in girls and women with galactosemia, first described by Kaufman and coworkers ([@DMV036C104], [@DMV036C105]), who observed POI in 12 of 18 (67%) galactosemic women. Later [@DMV036C223] reported that 17% (8/47) galactosemic women presented with ovarian failure. However, with regard to duarte galactosemia, a mild variant of GALT deficiency, no apparent ovarian dysfunction was reported ([@DMV036C10]). Pathogenesis involves excess galactose toxicity that impairs folliculogenesis, induces resistance to gonadotrophins and accelerates follicular atresia ([@DMV036C77]; [@DMV036C11]).

### Carbohydrate-deficient glycoprotein syndrome type I (CDG-Ia): phosphomannomutase 2 (PMM2) (16p13) {#s3c4}

In type 1 carbohydrate-deficient glycoprotein deficiency, also named phosphomannomutase deficiency, mannose-6-phosphate cannot be converted to mannose-1-phosphate. This lipid linked oligosaccharide is necessary for formation of secretory glycoproteins. Neurologic abnormalities and ovarian failure occur ([@DMV036C55]; [@DMV036C113]). Located on 16p13, *PMM2* is typically caused by a missense mutation ([@DMV036C18]).

### Proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1): noggin (NOG) (17q22) {#s3c5}

*NOG* encodes a secreted polypeptide that binds to and inactivates members of the TGF-β superfamily (i.e. BMP2, 4, 7, 14 and GDF5). NOG is expressed in various tissues including female reproductive organs. *NOG* mutations are known to explain proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) ([@DMV036C82]). In addition, [@DMV036C110] described a heterozygous mutation (p.E48K) in *NOG* in a female presenting with SYM1 and also having POI. However, [@DMV036C116] concluded the relationship between *NOG* mutations and non-syndromic POI was not clear, having screened the coding sequence of *NOG* in 100 non-syndromic sporadic POI patients and identifying only one heterozygous mutation (p.G92E) ([Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)). Actually this experience mirrors the situation involving other pleiotropic genes causing POI.

### Autoimmune regulation/autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED): autoimmune regulator (AIRE) (21q22.3) {#s3c6}

The *AIRE* gene can if perturbed lead to multi-system abnormalities: alopecia, vitiligo, keratopathy, malabsorption, hepatitis and mucocutaneous candidiasis. Ovarian hypoplasia often occurs, usually in the third decade ([@DMV036C224]). Many different *AIRE* perturbations have been found in this autosomal dominant disorder, not only nonsense mutations but also frame shifts. No particular mutation leads to ovarian failure as distinct from other autoimmune phenomena. *AIRE* mutations have not yet been sought in women with isolated POI (non-syndromic).

### Ovarian leukodystrophy: eukaryotic translation initiation factor (EIF2B): subunit 2 beta, 39 kDa (EIF2B2) (14q24.3); subunit 4 delta, 67 kDa (EIF2B4) (2p23.3); subunit 5 epsilon, 82 kDa (EIF2B5) (3q27.1) {#s3c7}

'Vanishing white matter' leads to variable but progressive neurological degeneration. Ovarian failure may coexist ([@DMV036C190]; [@DMV036C21]). That the causative gene (*EIF2B*) allows denatured stress-related proteins to accumulate makes plausible the relevance to oogenesis, given ongoing oocyte degeneration. [@DMV036C71] found variants in *EIF2B2*, *EIF2B4* and *EIF2B5* in seven POI cases with neurologic abnormalities, but in 93 non-syndromic POI none were found positive ([@DMV036C72]). Therefore, *EIF2B* genes have not yet been shown to be responsible for non-syndromic POI.

### Perrault syndrome: hydroxysteroid (17-beta) dehydrogenase 4, HSD17B4, 5q21; histidyl-tRNA synthetase 2, mitochondrial, HARS2, 5q31.3; leucyl-tRNA synthetase 2, mitochondrial, LARS2, 3p21.3; caseinolytic mitochondrial matrix peptidase proteolytic subunit, CLPP, 19p13.3; chromosome 10 open reading frame 2, C10orf2, 10q24 {#s3c8}

Perrault syndrome is a well-recognized pleiotropic autosomal recessive disorder characterized by ovarian failure in females, progressive sensorineural deafness in both males and females, and in some patients, neurological manifestations. Only recently have the underlying genes been identified and proved to be heterogeneous. In a family of mixed European ancestry with two sisters presenting with Perrault syndrome, compound heterozygous variants - c.650A\>G (p.Y217C) and c.1704T\>A (p.Y568X), in *HSD17B4* were found. Then with similar genomic strategies with linkage analysis or whole-exome sequencing (WES), mutations in *HARS2*, *LARS2*, *CLPP* and *C10orf2* have been found in the context of Perrault syndrome ([@DMV036C156], [@DMV036C157]; [@DMV036C97]; [@DMV036C139]). All these genes are essential for normal mitochondrial function. This group of causative genes is detailed in 'Mitochondrial Genes Causing POI' Section.

### Other pleiotropic disorders {#s3c9}

Table [III](#DMV036TB3){ref-type="table"} lists other nuclear genes causing syndromes in which POI is a feature. These include *POLG* associated with progressive external ophthalmoplegia (PEO, detailed in 'Mitochondrial Genes Causing POI' section), *BLM* with Bloom syndrome, *AIRE* with Ataxia telangiectasia, *WRN* with Werner syndrome and *RECQL4* with Rothmund--Thomson syndrome. A common feature of several is chromosomal breakage, best exemplified by Bloom syndrome ([@DMV036C200]; [@DMV036C199]).

In aggregate these and other conditions in Table [III](#DMV036TB3){ref-type="table"} explain no more than 1% of cases of POI. From a scientific perspective however, elucidating the role these genes play in reproduction offers novel clues to integrity needed for normal ovarian differentiation. Clinicians caring for females with these syndromes should thoroughly investigate and evaluate any reported menstrual irregularities.

Mitochondrial genes causing POI {#s3d}
-------------------------------

Perturbations of mitochondrial genes or nuclear genes affecting mitochondria are good candidates for POI because the mature oocyte has the greatest number of mitochondria of any human cell. Mature oocytes readily accumulate mitochondria during oogenesis, mitochondrial biogenesis playing an essential role in oocyte maturation, fertilization and embryo development. Dysregulation of mitochondrial dynamics contributes to excess oxidative stress and initiation of apoptosis, thus accelerating follicle depletion. A marked quantitative decrease of mitochondrial DNA (mt DNA) in oocytes and peripheral blood cells has been well documented in women with ovarian insufficiency ([@DMV036C136]; [@DMV036C22]). Thus, any gene affecting mitochondria involving muscular and neurological disturbance is a candidate, because these systems are so dependent on mitochondrial integrity. Genes governing mitochondrial functions may be located in the nucleus, like those discussed in 'Single Genes Causing Non-syndromic POI' section, or in mitochondria itself (mt DNA). To date, those of relevance to POI have been nuclear genes.

### Progressive external ophthalmoplegia (PEO): polymerase (DNA directed), gamma (POLG) (15q25) {#s3d1}

mtDNA mutations usually affect muscular and neurological systems. In progressive external ophthalmoplegia (PEO) clinical features are proximal myopathy, sensory ataxia and parkinsonism. The causative mutation lies in the gene encoding polymerase gamma (*POLG*), which is responsible for mtDNA replication and repair. In three of seven families studied by [@DMV036C129], POI cosegregated with PEO. A p.Y955C mutation in *POLG* was found in two of these three families. p.Y955C (tyrosine to cytosine) affects a highly conserved region, rending functional plausibility. Compound heterozygosity (N468D/A1105T) was observed by [@DMV036C148] in another 3-generation family in which multiple family members were affected with both PEO and POI. Mutation screening of *POLG* in *isolated* POI, has, however, yielded few perturbations. A single p.R953C mutation was found in 201 POI cases (0.5%) cumulatively reported by [@DMV036C214]. No novel mutations were identified in Italian and British women with POI ([@DMV036C148]; [@DMV036C22]; [@DMV036C64]) ([Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)). Therefore, *POLG* variation is not a common explanation for sporadic POI in the absence of clinical suspicion for other mitochondrial-associated physical signs.

### Perrault syndrome: HARS2, 5q31.3; LARS2, 3p21.3; CLPP, 19p13.3; C10orf2, 10q24 {#s3d2}

As reviewed in 'Pleiotropic Single Gene Disorders Having POI' Section, ovarian failure is one of the characterized features in Perrault syndrome in females. The genes listed encode mitochondrial tRNA synthetase, chambered protease and primase-helicase and have been found to harbor mutations responsible for POI in Perrault syndrome ([@DMV036C156], [@DMV036C157]; [@DMV036C97]; [@DMV036C139]). Through WES in a consanguineous Palestinian family and a nonconsanguineous Slovenian family with Perrault Syndrome, homozygous mutation c.1565C\>A (p.T522N) and compound heterozygous mutation c.1077delT and c.1886C\>T (p.T629M) in the *LARS2* gene were identified, respectively ([@DMV036C157]). WES was also performed in a nonconsanguineous family of mixed European ancestry, showing compound heterozygous mutations c.598C\>G (p.L200V) and c.1102G\>T (p.V368L) in the *HARS2* gene ([@DMV036C156]). The homozygous mutations c.433A\>C (p.T145P), c.440G\>C (p.C147S) and c.270+4A\>G in the *CLPP* gene were observed in three consanguineous Pakistani families with Perrault Syndrome ([@DMV036C97]). In a Japanese family, affected individuals carried compound heterozygous p.R391H and p.N585S in the *C10orf2* gene essential for replication of mtDNA; meanwhile compound heterozygous mutations p.W441G and p.V507I were responsible for this disease in another family of European ancestry ([@DMV036C139]).

In aggregate, the above supports a critical role for genes controlling mitochondria in the maintenance of ovarian function and their roles in non-syndromic POI warrant further investigation.

Multiple malformation syndromes characterized by POI {#s3e}
----------------------------------------------------

In other syndromes, POI or primary ovarian failure (gonadal dysgenesis) is accepted as one component but the causative gene has not been found. [Supplementary Table SIV](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1) lists these conditions. Of particular interest is POI associated with cerebellar ataxia ([@DMV036C198]).

Genome-wide studies in POI {#s3f}
--------------------------

Contemporary genetic strategies applied to locate susceptible loci or genes causing POI have extended beyond suspected candidate gene interrogations to genome-wide approaches. Approaches include linkage analysis in families with multiple affected members, CGH for CNV, genome-wide association studies (GWAS), genome-wide sequencing of exomes (WES) and, in the future, whole genome sequencing (WGS).

### GWAS {#s3f1}

In GWAS, also known as whole genome association study (WGAS), one examines many common genetic variants in different individuals to see if any variant is associated with a trait. In GWAS one searches agnostically through the entire genome to identify variants (SNPs) more common in cases than controls of similar ethnicity. No *a priori* expectations exist. Six GWAS have been performed to identify variants associated with POI, but not all adhered to accepted criteria. Sample sizes were often very small and replicates not sought (Table [IV](#DMV036TB4){ref-type="table"}). The first GWAS showed association with the PTH-responsive B1 gene (*PTHB1*) in a small discovery set of 24 women and 24 controls ([@DMV036C102]). [@DMV036C107] identified an association of an intron SNP in ADAM metallopeptidase with thrombospondin type 1 motif, 19 (*ADAMTS19*) with POI in a discovery set of only 99 Dutch women and 181 controls; no replication set existed. Laminin, gamma 1 (*LAMC1*) was then reported to be significantly associated with POI in Korea in 122 cases versus 242 controls ([@DMV036C164]). Table IVGenome-wide association studies for POI.[@DMV036C102][@DMV036C107][@DMV036C173])[@DMV036C164][@DMV036C145][@DMV036C26]EthnicityKoreanCaucasian (Dutch)ChineseKoreanDutchMiddle-EasternDiscovery set No. of cases249939124105 No. of controls241818952454 Associations in discovery set*PTHB1* at 7p14 showed strongest association.\
Ht1 GAAAG: POI-susceptible haplotype;\
Ht2 TGTGC: POI-resistant haplotype.rs246246 mapped to *ADAMTS19* intron8q22.3\
(10^−6^)22 SNPs in *LAMC1* associated with POISusceptible locus: 5q14.1-q15Susceptible loci: 7p21.1-15.3, 7q21.3-22.2Replication set No. of cases1016040098---- No. of controls8790800218---- Results of replication set*PTHB1* associated with POI; Ht1 confers susceptibility to POI.Association not confirmed.Frequencies of 9 SNPs and 1 haplotype were higher in POI than in control.--Sequencing three candidate genes *DLX5*, *DLX6* and *DSS1* did not reveal causal mutations[^7]

Our group conducted the largest GWAS with an initial discovery set of 391 cases versus 895 controls; the independent replication set consisted of 400 cases and 800 controls. The most signiﬁcant association was at 8q22.3 (1.6 × 10^−6^--3.86 × 10^−6^). This falls short of the canonical 10^−8^ expected to confer unequivocal significance. This region does not contain a protein coding candidate gene ([@DMV036C173]). However, it is now appreciated that 90% of significant GWAS associations are in intragenic or intergenic regions, portions of the 98.5% of the genome not coding for protein. These regions include a host of regulatory genes and networks (ENCODE). 8q22.3 may be an important yet undeﬁned long-distance regulatory region affecting ovarian differentiation and oogenesis. Disruption might lead to ovarian failure, analogous to disruption of the region upstream of Sex determining region Y-box 9 (*SOX9*) that causes XY sex reversal in mice and humans ([@DMV036C165], [@DMV036C166]). Replication in independent cohorts needs to be performed to determine potential causative roles.

GWAS have revealed multiple loci potentially associated with POI in Chinese, Korean, and Dutch women. However, in each it was difficult to implicate specific novel genes, and in none did significance exceed 10^−6^; positive findings were not always replicated. The most likely explanation for these data is limitation based on small sample size. In no study did sample number exceed 1000, thus lacking statistical power sufficient to detect a modest association when evaluating hundreds of thousands of SNPs. That POI is a rarer condition than polycystic ovary syndrome or endometriosis makes it difficult to accrue the requisite sample size possible in studying those disorders ([@DMV036C217]; [@DMV036C38]; [@DMV036C192]).

### GWAS involving family linkage analysis {#s3f2}

Table [IV](#DMV036TB4){ref-type="table"} includes two genome-wide association linkage studies involving single extended families. In a Dutch POI family subjected to a genome-wide linkage scan 5q14.1-q15 was found to be a susceptibility region ([@DMV036C145]). [@DMV036C26] performed genome-wide linkage and homozygosity analysis in a large consanguineous Middle-Eastern POI-affected family showing autosomal inheritance. Two regions---7p21.1-p15.3 and 7q21.3-q22.2---were identified as candidate regions by homozygosity mapping. However, sequencing the three most plausible candidate genes in this region---*DLX5*, *DLX6* and *DSS1*---failed to reveal mutations.

### GWAS involving age of menopause {#s3f3}

Insights derived from shared genetic susceptibility between POI and either age at natural menopause (AANM) or early menopause (EM) represent another potential path identifying novel entry points for unraveling genetic mechanism involved in POI. Thus, we gathered 36 SNPs shown from previous GWAS studies seeking SNPs associated with AANM or EM, plus 3 additional SNPs in *ESR1* and 2 additional SNPs in *PTHB1.* Differential association was then sought in 371 POI and 800 controls, all of Chinese Han origin ([@DMV036C174]). Three SNPs, rs2278493 in hexokinase 3 (*HK3*), rs2234693 in estrogen receptor 1 (*ESR1*) and rs12611091 in BR serine/threonine kinase 1 (*BRSK1*), showed nominally significant association with POI. Thus, a plausible relationship could exist between POI and *ESR1*, *BRSK1*, *HK3*.

### Cytogenomic studies (CNV) {#s3f4}

There is increasing interest toward whole genome studies based on CNVs. Using CGH, one can efficiently search for small duplications or deletions potentially associated with a complex trait (such as POI). The purpose of identifying CNVs is that they may contain or be linked to a causative gene for the disorder studied. Seven array CGH studies have identified CNVs associated with POI ([Supplementary Table SV](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)).

In 2009, [@DMV036C1] reported that 8 previously known CNVs in 99 POI French patients located near 5 potential candidate genes---Dynein, axonemal, heavy chain 5 (*DNAH5*), NLR family, apoptosis inhibitory protein (*NAIP*), Dual specificity phosphatase 22 (*DUSP22*), Nuclear protein, transcriptional regulator, 1 (*NUPR1*), and *AKT1*. However, this and all other CGH studies have the major pitfall of usually lacking information on parents. A large, *de novo*, CNV deletion is more likely to be pathogenic than an inherited CNV. Another array CGH study involving 74 German patients with POI or ovarian dysgenesis identified 44 losses or gains at autosomes and X chromosome that might explain POI ([@DMV036C123]). [@DMV036C137] identified 17 novel microduplications and 7 novel microdeletions among 89 POI patients, all but one located at autosomes. Included were two novel microdeletions causing haploinsufficiency for Synaptonemal complex central element protein 1 (*SYCE1*) and Cytoplasmic polyadenylation element binding protein 1 (*CPEB1*), genes known to cause ovarian failure in knockout mouse models ([@DMV036C20]; [@DMV036C143]). Recently, a high-resolution array CGH identified eleven unique CNVs in 11 patients with POI. Among these CNVs, a tandem duplication of 475 bp containing 3 *NOBOX*-binding elements and an E-box important for *GDF9* gene regulation in the promoter of *GDF9* is likely causative of POI ([@DMV036C142]).

Using a complete X chromosome tiling path array, [@DMV036C177] found 15 novel discrete X chromosome intervals in 20/42 (48%) women with POI in the UK. However, in patients from New Zealand, [@DMV036C63] detected only two microduplications (Xp22.33 and Xq13.3) in a low frequency of 4%. [@DMV036C108] found one CNV in Xq21.3 to be associated with POI, specifically in a region where Protocadherin 11 X-linked (*PCDH11X*) and TGFB-induced factor homeobox 2-like, X-linked (*TGIF2LX*) are located. Interestingly, no deletions were found in other regions, several considered on the basis of traditional cytogenetic studies to be pivotal ([@DMV036C201]).

Differing array CGH platforms and definitions for pathogenicity probably explain some of the discrepant results among the above studies. Also problematic is the limited sample size and lack of parental studies to exclude a CNV ostensibly associated with POI merely having been transmitted from a normal mother.

### WES {#s3f5}

Low prevalence and impaired fecundity resulting in limited numbers of POI pedigrees without associated somatic anomalies (non-syndromic) has led to increasing application of WES, another agnostic approach. WES has identified several genes in POI not previously anticipated.

In POI associated with somatic features, causative perturbations have been found by WES for *HSB17B4*, *LARS2*, *CLPP* and *C10orf2* in Perrault syndrome ([@DMV036C155], [@DMV036C157]; [@DMV036C97]; [@DMV036C139]) (detailed in 'Mitochondrial Genes Causing POI' section and Table [V](#DMV036TB5){ref-type="table"}). Up to the present, there have been six WES conducted in non-syndromic POI pedigrees. Interestingly, almost all plausible candidate genes identified were involved in meiosis and DNA repair (Table [V](#DMV036TB5){ref-type="table"}). Table VWhole-exome sequencing for syndromic or isolated POI.GeneLocationMutationFunctionCompound Het/Homo/HetReference*HSB17B4*5q21c.650A\>G (p.Y217C); c.1704T\>A (p.Y568X)Reduced expression with mutant proteinCompound heterozygous[@DMV036C155]*CLPP*19p13.3c.433A\>C (p.T145P),Alter the structure of the CLPP barrel chamber that captures unfolded proteins and exposes them to proteolysisHomozygous[@DMV036C97]c.440G\>C (p.C147S)c.270+4A\>GWeakens donor splice-site function*LARS2*3p21.3c.1565C\>A (p.T522N)Partially functional in Yeast complementation assayHomozygous[@DMV036C157]c.1077delT;\
c.1886C\>T (p.T629M)Nonfunctional in Yeast complementation assayCompound heterozygous*C10orf2*10q24c.1172G\>A (p.R391H) c.1754A\>G (p.N585S)Affect interactions of the linker domain\
Likely affect enzyme activityCompound heterozygous[@DMV036C139]c.1321T\>G (p.W441G) c.1519G\>A (p.V507I)Affect interactions of the linker domainCompound heterozygous*HFM1*1p22.2c.1686-1G\>C\
c.2651T\>G (p.I884S)Compound heterozygous[@DMV036C233]c.2206G\>A (p.G736S); c.3929_3930 delinsG, (p.P1310R fs\*41)Compound heterozygous*MCM9*6q22.31c.1732+2T\>CAbnormal splicing and truncated protein that are unable to be recruited to sites necessary for DNA damageHomozygous[@DMV036C238]c.394C\>T (p.R132\*)Repair of chromosome breaks impaired in lymphocytesHomozygous*STAG3*7q22.1c.968delC (p.F187fs\*7)Homozygous[@DMV036C27]*SYCE1*10q26.3c.613C\>T (p.Q205\*)Homozygous[@DMV036C54]*MCM8*20p12.3c.446C\>G (p.P149R)Impedes the repair of MMC-induced chromosomal breaks; inhibits MCM8 recruitment to sites of DNA damage; impairs DNA binding ability at the N-terminusHomozygous[@DMV036C6]*eIF4ENIF1*22q11.2c.1286C\>G (p.S429\*)Heterozygous[@DMV036C103][^8]

#### ATP-dependent DNA helicase homolog (HFM1) (1p22.2) {#s3f5a}

*HFM1*, a meiotic gene encoding DNA helicase preferentially expressed in germ-line tissues such as testis and ovary, is necessary for homologous recombination and synapsis during meiosis ([@DMV036C210]). *Hfm1*^−/−^ female mice had significantly reduced ovaries and follicle numbers and an increase in stromal cells ([@DMV036C85]). The recent report by [@DMV036C233]) identified a compound heterozygous mutation (c.1686-1G\>C and c.2651T\>G, p.I884S) in the *HFM1* gene in two affected Chinese sisters. Screening for *HFM1* mutations in a cohort of 69 Chinese women with sporadic POI identified another patient with compound heterozygous mutations (c.2206G\>A, p.G736S and c.3929_3930 delinsG, p.P1310R fs\*41). These variants were not found in 316 matched controls or databases.

#### Minichromosome maintenance complex component 8 and 9 (MCM8, 20p12.3; MCM9, 6q22.31) {#s3f5b}

*MCM8* and *MCM9,* recently discovered members of the highly conserved mini-chromosome maintenance proteins (MCM), are genes implicated in homologous recombination and repair of double-stranded DNA breaks. The MCM8/MCM9 complex is required for the resolution of dsDNA breaks that occur during homologous recombination in pachytene of meiosis I. Failure to resolve breaks predictably leads to oocyte death and small or absent ovaries. *Mcm8* and *Mcm9-*deficient mice are infertile and have small gonads due to germ cell depletion ([@DMV036C130]). Recently, Rajkovic and colleagues ([@DMV036C6]; [@DMV036C238]) discovered homozygous mutations in *MCM8* and *MCM9* genes in consanguineous families with POI (primary amenorrhea), using WES. One of the two mutations found in *MCM9* is c.1732+2T\>C, which resulted in abnormal alternative splicing and truncated forms of MCM9 that are unable to be recruited to sites of DNA damage. The other mutation c.394C\>T (p.R132\*) results in loss of function of MCM9. It is suspected that preferential sensitivity of germline meiosis to MCM9 functional deficiency and compromised DNA repair in the somatic component most likely account for the ovarian failure and short stature. A homozygous mutant c.446C\>G (p.P149R) found in *MCM8* inhibited recruitment of MCM8 to sites of DNA damage and led to genomic instability. ASNP rs16991615 in *MCM8* was also found associated with the age of natural menopause in the GWAS previously discussed ([@DMV036C40]). The role the novel *MCM8/MCM9* pathway plays in women with idiopathic POI needs to be explored further.

#### Stromal antigen 3 (STAG3) (7q22.1) {#s3f5c}

*STAG3* encodes a subunit of cohesin, a large protein complex that is essential for proper pairing and segregation of chromosomes during meiosis. A homozygous frameshift mutation resulting from a 1-bp deletion (c.968delC, p.F187fs\*7) in *STAG3* was identified in a highly consanguineous Palestinian pedigree; in which a 10-Mb region on 7q21.3--22.2 and a 3-Mb region on 7p21.1--15.3 had been previously identified to show significant linkage with the POI phenotype ([@DMV036C26], [@DMV036C27]). Deficiency of *Stag3* in female mice results in severe and early ovarian dysgenesis, with distinctive lack of oocytes and ovarian follicles. Early meiotic arrest and the centromeric chromosomal cohesion defects were observed in *Stag3^−/−^*fetal oocytes providing further evidence that *Stag3* is essential for assembly of the meiotic cohesin ring and the synaptonemal complex ([@DMV036C27]).

#### Synaptonemal complex central element 1 (SYCE1) (10q26.3) {#s3f5d}

The *SYCE1* gene encodes a component of the synaptonemal complex where paired chromosome homologs closely associate in meiosis (synapsis) before crossover. *Syce1*^−/−^ mice were infertile with smaller gonads, and showed loss of follicles in ovaries and postmeiotic cells in testis. Early meiosis arrest at prophase\\xE2\\x85followed by cell apoptosis could explain the phenotype ([@DMV036C20]). Different microdeletions of *SYCE1* have also been reported in Caucasian and Chinese POI patients ([@DMV036C137]; [@DMV036C251]). In a consanguineous Israeli Arab family, a homozygous nonsense mutation (c.613C\>T, p.Q205\*) in *SYCE1* was identified in two sisters with primary amenorrhea, presumably inherited in autosomal recessive fashion ([@DMV036C54]).

#### Eukaryotic translation initiation factor 4E nuclear import factor 1 (eIF4ENIF1) (22q11.2) {#s3f5e}

eIF4ENIF1, a transport protein, plays an important role in repressing translation through eIF4E. Both genes appear to play important roles in ovarian germ cell development ([@DMV036C219]). A heterozygous nonsense mutation (c.1286C\>G, p.S429\*) was identified in *eIF4ENIF1*, segregating with ovarian insufficiency (menopause age 29--35 years) in a large French Canadian family. No additional mutations were identified in *eIF4ENIF1* or *eIF4E* in 38 unrelated women with isolated POI. Haploinsufficiency or nuclear sequestration might disrupt the development of a normal oocyte complement ([@DMV036C54]).

The whole exome studies in familial POI mentioned above mainly involve genes crucial during meiosis, such as generating and repairing DSBs, chromosome synapsis and recombination, and sister chromatid cohesion. This implies that perturbation of genes encoding proteins that regulate meiosis can result in autosomal recessive primary ovarian insufficiency in humans. Despite some negative candidate gene results with meiotic genes (*DMC1*, *SPO11* and *MSH4*) in POI, WES results still provide reasons to pursue other genes participating in meiosis and DNA repair in ubiquitous pathways.

### NGS {#s3f6}

Future studies on targeted candidate genes of POI can be anticipated using NGS. A recent abstract ([@DMV036C75]) reported a study of 12 POI cases having non-syndromic POI and 176 control women whose menopause had occurred after age 50 years. A further 345 women from the same ethnic origin were stated to be recruited to assess allele frequency for potentially deleterious sequence variants. In the 12 POF cases, complete coding regions of 70 candidate genes were fully sequenced with mutations claimed in *ADAMTS19*, *BMPR2* and *LHCGR* genes. Full details are awaited.

Regulatory genes and networks {#s3g}
-----------------------------

Seeking POF genes has to date largely focused on coding variants, presuming plausible protein disruption. However, only 1.5% of the genome is protein-coding. Indeed, many POF-associated variants in whole genome studies map within, or in linkage disequilibrium to, intronic or intergenic regions; thus, these regions likely contain causative regulatory genes or networks. In our own POI GWAS, for example, 'gene desert' 8q22.3 was the region of most significance by association ([@DMV036C173]).

Non-coding variants must be more robustly interrogated. Perturbations sought should include involving non-coding RNA (microRNA \[miRNA\], long non-coding RNA \[lncRNA\]), disruption or creation of alternative splicing or transcription factor-binding sites, and epigenetic modifications (DNA methylation patterns, chromatin modification). Large epigenetic consortia, such as ENCODE (<http://genome.ucsc.edu/ENCODE/>), Roadmap (<http://www.roadmapepigenomics.org/>) and iHEC (<http://www.ihec-epigenomes.org/>) point to approaches used to characterize the regulatory landscape of susceptibility regions for specific cell types. Unfortunately, ENCODE ([@DMV036C17]; [@DMV036C66]; [@DMV036C204]) bypassed the reproductive track (males and females), and thus an ovarian ENCODE does not yet exist.

In order to generate the reproductive ENCODE, human ovarian tissue of specific cell types must be studied. Then, differences in regulatory genes between affected and normal individuals can be determined. Massive parallel sequencing using RNA-seq, or Methyl-seq will facilitate a systematic study of the transcriptome in ovaries in relation to genotypes and variants in POI. Chromatin immunoprecipitation followed by sequencing (ChIP-Seq) and RNA-Seq can also help identify novel transcriptional and epigenetic regions and, hence, mechanisms that potentially underlie POI. To analyze the complete proteomes and quantification of post-translational modifications, mass spectrometry would be the most attractive approach.

Having accumulated the requisite information, network and pathway-based analyses of assembled datasets can be assembled using systems biology approaches. Cascades of transcriptional regulation can be evaluated simultaneously, identifying overlap among genes or putative networks that currently constrain key variables in model systems.

The ultimate proof that an identified variant has a pathological effect traditionally relies on constitutive or conditional knock in/out or cell lines with a mutation signature. Increasingly, other approaches will be utilized. Patient-specific induced pluripotent stem cells (iPSCs) lines might offer an individually targeted genetic model system to identify and manipulate pathologic pathway. Use of iPSCs should be of particular value in assessing regulatory genes, which may have a quantitative deleterious effect rather than 'all or none' qualitative effect, observed or assumed, in missense or nonsense protein-coding mutations.

Conclusion: current status of genes causing POI {#s4}
===============================================

The POI---causative genes surveyed and found to date allow us to reach several conclusions.

*First*, many genes have emerged as POI candidates (Fig. [1](#DMV036F1){ref-type="fig"}), but in non-syndromic POI only a minority have been proven equivocally causative by functional validation. These include *BMP15*, *PGRMC1*, and *FMR1* premutation on the X chromosome and on autosomes *GDF9*, *FIGLA*, *FSHR, NOBOX*, *NR5A1*, *NANOS3*, *STAG3*, *SYCE1*, *MCM8/9* and *HFM* 1. No perturbations have been found in a dozen other plausible candidates for which murine knockouts show ovarian failure, but this may simply reflect small sample sizes or interrogation restricted to a single ethnic group. Figure 1Schematic representation of chromosomal location of plausible genes associated with primary ovarian insufficiency.

*Second*, notable differences in frequency exist among different populations. This is predictable for any genetic condition, and in POI this has already been observed in *FSHR*, *BMP15*, *NOBOX*, *FOXL2*, *TGFBR3*, *CDKN1B* and *FOXO3A* ([Supplementary Table SII](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv036/-/DC1)). Future genetic studies should involve different ethnic groups and larger sample sizes. Clinically, caution should apply when counseling on the basis of data derived from an ethnic group different from that of the counseled individual.

*Third*, causative POI genes are increasingly being shown not only to be restricted to expression in ovaries but also expressed ubiquitously. True, POF5 (*NOBOX*) and POF6 (*FIGLA*) are restricted to the ovaries. However, *PTEN* is a major regulator of the PI3K pathway involved in systemic cell proliferation, survival, migration and metabolism. PTEN also plays a vital role in the activation of primordial follicles. The spectrum of candidate genes potentially causing POI is being enriched.

*Fourth*, many genes that currently appear isolated in function actually may be interrelated within yet to be defined pathways. It is logical to stratify by gene function in ostensibly distinct systems: endocrine, folliculogenesis, cell cycle, meiosis, mitochondrial, as examples. More difficult are gene-gene or protein-protein interactions, acting in ways not yet evident. This review thus unavoidably overestimates the role that protein-coding genes play to the detriment of upstream and downstream regulatory genes. Until recently, exome studies had to be restricted to sequencing individual candidate genes. Continued advances in sequencing techniques and contemporary bioinformatives will facilitate finding additional genes responsible for POI in other portions of the genome.

*Fifth*, elucidating the etiology and molecular basis of POI is of paramount importance not only in understanding ovarian physiology but also in providing genetic counseling and fertility guidance. Once additional variants are detected, it will be increasingly possible to predict the age of menopause. Women having certain perturbations of POI can be offered the option of oocyte cryopreservation, with later thawing and use in assisted reproductive technology at the appropriate age.
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[^1]: Chromosomal 'abnormalities' means visible structural changes in karyotype that are sufficiently large to cause clinical abnormalities. Variants (e.g. prominent satellites) are not included.

[^2]: CA, chromosomal abnormalities; PA, primary amenorrhea; POI, primary ovarian insufficiency; SA, secondary amenorrhea; EM, early menopause.

[^3]: ^a^Including 2 46,XY gonadal dysgenesis (Swyer syndrome).

[^4]: MR: mutation rate; FC: functional confirmation; BMP15: bone morphogenetic protein 15; AR: androgen receptor; FOXO4: forkhead box O4; POF1B: premature ovarian failure, 1B; DACH2: dachshund family transcription factor 2; PGRMC1: progesterone receptor membrane component-1.

[^5]: ^a^Only refer to novel missense, frameshift and nonsense mutations

[^6]: FMR1: Fragile X mental retardation 1; FOXL2: forkhead box L2; GALT: galactose 1-phosphate uridyl transferase; AIRE: autoimmune regulator; EIF2B: eukaryotic translation initiation factor; POLG: polymerase (DNA directed), gamma; NOG: noggin; PMM2: Phosphomannomutase 2; HSD17B4: Hydroxysteroid (17-beta) dehydrogenase 4; HARS2: Histidyl-tRNA synthetase 2, mitochondrial; CLPP: caseinolytic mitochondrial matrix peptidase proteolytic subunit; LARS2: leucyl-tRNA synthetase 2, mitochondrial; C10orf2: Chromosome 10 open reading frame 2; BLM: Bloom syndrome, RecQ helicase-like; ATM: ATM serine/threonine kinase; WRN: Werner syndrome, RecQ helicase-like; RECQL4: RecQ protein-like 4.

[^7]: PTHB1: Bardet--Biedl syndrome 9 (BBS9); ADAMTS19: ADAM metallopeptidase with thrombospondin type 1 motif, 19; LAMC1: laminin, gamma 1; DLX5, 6: distal-less homeobox 5 and 6; DSS1: split hand/foot malformation (ectrodactyly) type 1.

[^8]: HSD17B4: Hydroxysteroid (17-beta) dehydrogenase 4; CLPP: Caseinolytic mitochondrial matrix peptidase proteolytic subunit; LARS2: leucyl-tRNA synthetase 2, mitochondrial; C10orf2: Chromosome 10 open reading frame 2; HFM1: ATP-dependent DNA helicase homolog; MCM8, MCM9: minichromosome maintenance complex component 8 and 9; STAG3: stromal antigen 3; SYCE1: synaptonemal complex central element; eIF4ENIF1: eukaryotic translation initiation factor 4E nuclear import factor 1.
